Trastuzumab Emtansine
Metastatic Malignant Neoplasm In The Brain
Explore 101 assets in Metastatic Malignant Neoplasm In The Brain →Floatz Rating
CCC55/100
Confidence
Indicative
Sponsor
M.D. Anderson Cancer Center
Modality
antibody_drug_conjugate
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
45High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05673928CT.gov A Phase II Study of Tucatinib and Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2-positive Metastatic Solid Tumors and Metastases to Brain (TUCATEMEB) | — | Recruiting | — | — | — |
NCT05323955CT.gov Secondary BRain Metastases Prevention After Isolated Intracranial Progression on Trastuzumab/Pertuzumab or T-DM1 in Patients With aDvanced Human Epidermal Growth Factor Receptor 2+ brEast Cancer With the Addition of Tucatinib | — | Active Not Recruiting | — | — | — |
NCT04856475CT.gov Evaluation of Neratinib for Treatment and Prevention of Subsequent CNS Event(s) in Patients With Brain Metastasis of Advanced HER2 Positive Breast Cancer | — | Withdrawn | — | — | — |
NCT04158947CT.gov A Study of HER2+ Breast Cancer Patients With Active Brain Metastases Treated With Afatinib & T-DM1 vs. T-DM1 Alone | — | Unknown | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Metastatic Malignant Neoplasm In The Brain
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Trastuzumab Emtansine (this asset) | M.D. Anderson Cancer Center | P2 | CCC · 55 |
| Trastuzumab | Iambic Therapeutics, Inc | P4 | BB |
| Icotinib | Betta Pharmaceuticals Co., Ltd. | P3 | BB |
| Trastuzumab Deruxtecan | Baptist Health South Florida | P4 | BB |
| Capecitabine | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | P3 | BB |
| Copper Cu 64-Dota-Trastuzumab | City of Hope Medical Center | P4 | BB |
| Regorafenib | Neonc Technologies, Inc. | P2 | BB |
| Memantine | NRG Oncology | P3 | BB |
| Gefitinib | Alpha Biopharma (Jiangsu) Co., Ltd. | P3 | B |
+42 more in the Metastatic Malignant Neoplasm In The Brain cohort
Other indications for Trastuzumab Emtansine
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Breast Cancer | — | P3 | BB · 66 |
| Breast Carcinoma | — | P3 | BB · 66 |
| HER2 Positive Breast Carcinoma | — | P4 | BB · 66 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Trastuzumab Emtansine in Metastatic Malignant Neoplasm In The Brain. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/trastuzumab-emtansine-metastatic-malignant-neoplasm-in-the-brain
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →